The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01X | Other antineoplastic agents | |
| 4 | L01XA | Platinum compounds | |
| 5 | L01XA04 | Satraplatin |
| Active Ingredient | Description | |
|---|---|---|
| Satraplatin |
Satraplatin is a cytotoxic agent. The primary cytotoxic mechanism of satraplatin is similar to that of other platinum compounds including cisplatin, carboplatin and oxaliplatin, and is based on the formation of DNA adducts. Platinum-DNA adducts, which are formed following uptake of the drug into the nucleus of the cell, activate several cellular processes that mediate the cytotoxicity of these drugs. These processes include the signalling of DNA damage, cell cycle checkpoints and arrest, DNA repair and cell death. |
